Table 1.
Patient characteristics
| Parameter | All patients | Patient’s with biochemical failure | ||
|---|---|---|---|---|
| N=203 | % | N=30 | % | |
| Age (year) | ||||
| Median (range) | 75 (56–89) | - | 74.5 (56–86) | - |
| Clinical stage | ||||
| T1-T2a | 39 | 19.2 | 3 | 10 |
| T2b-c | 65 | 32 | 10 | 33.3 |
| T3a | 62 | 30.5 | 9 | 30 |
| T3b-T4 | 37 | 18.3 | 8 | 26.7 |
| Gleason score | ||||
| ≤ 6 | 15 | 7.4 | 1 | 3.3 |
| 7 | 45 | 21.2 | 8 | 26.7 |
| 8–10 | 143 | 70.4 | 21 | 70 |
| PSA | ||||
| Median (range) | 16 (1.4–449) | - | 22.7 (1.4–449) | - |
| <10 | 71 | 35 | 8 | 26.66 |
| 10–20 | 48 | 23.6 | 6 | 20 |
| 20.1–39.9 | 51 | 25.1 | 5 | 16.66 |
| ≥40 | 33 | 16.3 | 11 | 36.66 |
| >4 cores positive with Gleason 8–10 | ||||
| ≤4 | 109 | 53.7 | 12 | 40 |
| >4 | 82 | 40.4 | 17 | 56.7 |
| Unknown | 12 | 5.9 | 1 | 3.3 |
| Primary Gleason pattern | ||||
| <5 | 186 | 91.6 | 25 | 83.3 |
| 5 | 17 | 8.4 | 5 | 16.7 |
| NCCN risk group | ||||
| High risk | 100 | 49.3 | 11 | 36.7 |
| VHR | 103 | 50.7 | 19 | 63.3 |
| RT technique | ||||
| 3D | 29 | 14.3 | 6 | 20 |
| IMRT | 60 | 29.6 | 11 | 36.7 |
| VMAT | 114 | 56.1 | 13 | 43.3 |
| ADT use | ||||
| Yes | 197 | 97 | 28 | 93.3 |
| No | 6 | 3 | 2 | 6.66 |
| Duration ≤ 6 mo | 14 | 6.9 | 0 | 0 |
| Duration 6–24 mo | 9 | 4.4 | 2 | 6.66 |
| Duration ≥ 24 mo | 174 | 85.7 | 26 | 86.66 |
| Prostate radiation dose | ||||
| <78 Gy 2 Gy/fx. | 5 | 2.5 | 1 | 3.3 |
| 78–82 Gy 2 Gy/fx | 97 | 47.8 | 18 | 60 |
| 73.6 Gy 2.3 Gy/fx | 101 | 49.7 | 11 | 36.7 |
| Pelvic lymph node RT | ||||
| Yes | 201 | 99 | 30 | 100 |
| No | 2 | 1 | 0 | 0 |
| 46 Gy | 88 | 43.3 | 16 | 53.3 |
| 54.4 Gy | 113 | 55.7 | 14 | 46.7 |